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Objectives: Evidence synthesis is an integral part
decision-making by reimbursement agencies. When
direct evidence is not available, network-meta-analysis
(NMA) techniques are commonly used. This approach
assumes that the trials are sufficiently similar in terms
of treatment-effect modifiers. When imbalances in
potential treatment-effect modifiers exist, the NMA
approach may not produce fair comparisons. The
objective of this study was to identify and quantify the
interaction between treatment-effect and potential
treatment-effect modifiers, including time-of-response
measurement and baseline viral load in chronic
hepatitis B (CHB) patients.
Design: Retrospective patient-level data econometric
analysis.
Participants: 1353 individuals from two randomised
controlled trials of nucleoside-naïve CHB taking 0.5 mg
entecavir (n=679) or 100 mg lamivudine (n=668) daily
for 48 weeks.
Interventions: Hepatitis B virus (HBV) DNA levels for
both drugs were measured at baseline and weeks 24,
36 and 48. Generalised estimating equation for
repeated binary responses was used to identify
treatment-effect modifiers for response defined at
≤400 or ≤300 copies/ml.
Primary outcome measures: OR at 48 weeks.
Results: The OR for the time-of-response
measurement and treatment-effect interaction term was
1.039 (p=0.00) and 1.035 (p=0.00) when response
was defined at ≤400 or ≤300 copies/ml, respectively.
The baseline HBV DNA and treatment-effect interaction
OR was 0.94 (p=0.047) and 0.95 (p=0.096),
respectively, for the two response definitions
suggesting evidence of interaction between baseline
disease activity and treatment effect. The interaction
between HBeAg status and treatment effect was not
statistically significant.
Conclusions: The measurement time point seems to
modify the relative treatment effect of entacavir
compared to lamivudine, measured on the OR scale.
Evidence also suggested that differences in baseline
viral load may also alter relative treatment effect. Meta-
analyses should account for such modifiers when
generating relative efficacy estimates.
INTRODUCTION
Chronic hepatitis B (CHB) is an infectious
condition caused by the hepatitis B virus
(HBV). Long-term consequences of infection
include cirrhosis, hepatocellular carcinoma
and ultimately death.1 For patients in the UK,
the licensed treatments for CHB are entecavir
(ETV), lamivudine (LAM), telbivudine, adefo-
vir dipivoxil, tenofovir disoproxil fumerate
(TDF), peginterferon α-2a, interferon α-2a
and interferon α-2b.2 These treatments have
been evaluated in randomised controlled trials
(RCTs); however, head-to-head comparisons
ARTICLE SUMMARY
Article focus
▪ In patients with chronic hepatitis B, are there any
baseline patient characteristics that impact on the
probability of achieving undetectable viral load
after 1 year of therapy?
▪ If so, what is the magnitude of the effect?
Key messages
▪ Time on treatment and baseline viral load were
independent treatment-effect modifiers.
▪ The treatment–effect interaction OR for baseline
viral load was 0.94 (p=0.047).
▪ Future meta-analyses should account for this
interaction term in order to generate ‘like-for-like’
comparisons.
Strengths and limitations of this study
▪ Analyses based on patient-level data from two
high-quality randomised controlled trials (patient
count=1353).
▪ The statistical models took account of the longi-
tudinal nature of the data and the correlation
between repeated measures.
▪ HBV DNA levels were observed at relatively small
number of discrete time points, that is, 24, 36
and 48 weeks
▪ Only two treatments included in the trials (ente-
cavir and lamivudine).
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are not always available for all possible treatment compari-
sons. From the perspective of a reimbursement agency
such as the National Institute for Health and Clinical
Excellence (NICE), this poses a challenge since relative
estimates of the treatment efﬁcacy may not be available for
each intervention to inform reimbursement decisions.
One strategy to overcoming this challenge is to use
network meta-analysis (NMA) to generate relative efﬁ-
cacy estimates between competing treatments.3–6 While a
traditional meta-analysis includes studies that compare
two interventions with each other, an NMA synthesises
all available evidence from a network of RCTs involving
multiple treatments compared directly or indirectly or
both. NMA extends the concept of a traditional
meta-analysis by including multiple pairwise compari-
sons across a range of interventions and provides esti-
mates of the relative treatment effect on multiple
treatment comparisons by using a chain of evidence that
links treatments of interest. It represents a comprehen-
sive analysis framework for combining both direct and
indirect evidence in such a manner as to preserve ran-
domisation within trials.
The NMA approach allows consideration of all rele-
vant evidence and addresses research questions in the
absence of direct comparative evidence, thus improving
the precision of estimates by combining direct and indir-
ect evidence. One of the key assumptions underpinning
this method is that the studies included in the analysis
are homogeneous, that is, the trials are sufﬁciently
similar on study and patient characteristics (‘covariates’).
If these covariates act as modiﬁers of the relative treat-
ment effect (ie, the difference in response on a given
scale, typically log-odds or odds) and their distribution is
not balanced across the studies that are compared dir-
ectly or indirectly, the similarity assumption is violated
and the NMA is affected by confounding bias. Effect
modiﬁers may include patient characteristics, study
setting, length of follow-up, outcome deﬁnition and
measurement and study methodology (eg, protocol
requirements and study time frame).7 This is particularly
important in cases where response to treatment is
deﬁned in terms of post-treatment level of a measure
(eg, a biological marker such as response viral load)
when the baseline level of this measure is known to vary
across studies. As a result, if one study happens to
recruit patients with a more advanced disease (ie, worse
levels of a given clinical variable), and this variable is
known to modify the impact of treatment, then the level
of response achieved in this study is likely to be smaller
compared to another study which primarily includes
patients with less-advanced disease (ie, with better base-
line variable levels), all things being equal. To identify
treatment-effect modiﬁers and to provide an estimate of
the magnitude of treatment–covariate interaction,
regression analysis of individual patient-level data can be
used. This, in turn, can form the basis for evaluating
baseline imbalances across trials included in the NMA. It
should, however, be noted that such within-trial
interaction analysis would provide an estimate for the
magnitude of potential treatment modiﬁer effect rather
than proving beyond doubt that these interactions exist
at the study level.
To date, two network meta-analyses of treatments for
CHB have been published in peer-review journals.8 9
Both studies deﬁned response to treatment in terms of
attainment of undetectable levels of HBV DNA below a
predeﬁned threshold at a given time point. However, in
both cases, the authors did not attempt to fully account
for the differences in different sources of heterogeneity,
including baseline patient characteristics across different
trials. Moreover, the effect of using different deﬁnitions
of virological response to treatment was not explored
during evidence synthesis.
The objective of this study was to explore and quantify
the relationship between treatment effect and patient
characteristics, in particular, baseline disease severity
and time-of-response measurement, in predicting
response to CHB treatment. Baseline HBV DNA level as
measured using the PCR assay is known to be a pre-
dictor of treatment response but the extent of this rela-
tionship, and whether or not it is also a treatment-effect
modiﬁer (ie, whether or not it impacts on the efﬁcacy of
a particular treatment option) is not currently known.
This work is of interest to the clinical community since it
would provide evidence on whether and how much
treatment effects vary based on these variables. It will
also be of value in future network meta-analyses since it
explores the methodological implications of treatment
interactions that can impact on the observed level of
response. Extending network meta-analysis models with
treatment-by-covariate interactions may explain hetero-
geneity in relative treatment effects.
We used individual patient level data (IPD) from two
clinical trials of CHB patients, comparing ETV and
LAM, to quantify the relationship between treatment
effect and baseline covariates and time-of-response meas-
urement to identify any treatment-effect modiﬁers.
Treatment response was deﬁned in terms of attainment
of undetectable levels of HBV DNA below predeﬁned
threshold values of ≤400 and ≤300 copies/ml.
METHODS
Patient-level data from 1353 treatment-naïve individuals
recruited into two multinational double-blinded, double-
dummy studies of ETV 0.5 mg once daily (n=679) and
LAM 100 mg once daily (n=668) were made available by
Bristol-Myers Squibb for the purpose of this analysis
(study names: 022 and 027).10 11 In both clinical trials,
all individuals were nucleoside-naïve with the common
composite primary efﬁcacy endpoint being histological
improvement (≥two point decrease in the Knodell
necroinﬂammatory score) and no worsening of ﬁbrosis
(≥one point increase in the Knodell ﬁbrosis score), at
week 48, compared to baseline. Individuals were
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HBeAg-positive in Study 022 and HBeAg-negative in the
Study 027.
The primary rationale for the study was to explore the
effect of interaction between baseline variables and
treatment effect in predicting response. Here, response
is deﬁned as a binary (yes/no) variable in terms of
achieving a threshold of undetectable levels of HBV
DNA. Two commonly used response thresholds were
evaluated in this study, that is, ≤400 or ≤300 copies/ml
measured by PCR assay. Response was evaluated for each
individual patient at weeks 24, 36 and 48. The following
covariates were used in the statistical analysis: natural log
of baseline HBV DNA measured by PCR assay (variable:
‘LPCR_0’), treatment received (‘ETV’ or ‘LAM’, with
LAM used as the reference group), HBeAg antigen
status of the patient (‘HBeAg’) and a time variable
(‘TIME’) expressed in weeks to evaluate the impact of
duration on treatment response. The following inter-
action terms were included: treatment with ETV and
baseline viral load (‘ETV*PCR’), treatment with ETV
and time (‘ETV*TIME’) and treatment with ETV and
e-antigen status (ETV*HBeAg). Study-speciﬁc intercepts
were also included in the analysis. Covariates were
centred at their mean values, except for the time vari-
able which was centred at 48 weeks.
Statistical analysis was performed using the generalised
estimating equations (GEE) with logit link function and
autoregressive correlation structure. The use of GEE is
preferred when outcomes are correlated and the focus
of analysis is on estimating average effect in the popula-
tion. The GEE takes an account of the correlation
between repeated observations from the same individual
at multiple time points. Moreover, since the sample size
needed to achieve adequate statistical power to detect
interaction effects is larger than the sample size needed
to detect main effects,12 the use of GEE is preferred
over cross-sectional logistic regression as it allows the use
of multiple observations per individual. The analysis was
conducted in Stata V.11 (StataCorp. 2009. Stata
Statistical Software: Release 11. College Station, Texas:
StataCorp LP).
RESULTS
To contextualise the results of the statistical analysis con-
ducted in this study, we present the summary statistics
from a systematic review of CHB interventions con-
ducted separately by the authors and presented at the
International Society for Pharmacoeconomics and
Outcomes Research conference in 2011. Table 1 pre-
sents baseline HBV DNA levels in the RCTs of CHB
interventions. The table shows that the baseline HBV
DNA values in all trials ranged from 5.6 to 10.3 log10
copies/ml.
For HBeAg-positive patients, the range was between
5.7 and 10.3 log10 copies/ml, whereas for
HBeAg-negative patients, the range was 5.6–7.8 log10
copies/ml. Of note, however, is that when the focus is
restricted to the key HBeAg-positive regulatory trials for
ETV and TDF (AI463-022 and Marcellin2008), there is
an approximate difference of 1 log10 copies/ml. The
corresponding difference between the values in the ETV
and TDF in HBeAg-negative regulatory studies
(AI463-023 and Marcellin2008) was approximately
0.5 log10 copies/ml. Hence, the studies appear dissimilar
in terms of baseline viral load levels.
GEE logit regression models evaluated the odds of
achieving treatment response at two threshold values (ie,
HBV DNA ≤400 or ≤300 copies/ml) after adjusting for
baseline characteristics. Both main effect and interaction
terms were included in the analysis. The results are pre-
sented as both log-ORs (tables 2 and 3) and ORs (tables
4 and 5) with CIs. An OR of <1 suggests a decrease in
odds of achieving treatment response when the level of
baseline variable increases by one unit, and vice versa.
The results show that the coefﬁcient on the inter-
action term for treatment and baseline log-PCR
(ETV*PCR) is negative for both threshold values (tables
2 and 3) with different levels of statistical signiﬁcance.
The odds for the interaction term for response at
≤400 copies/ml were found to be 0.94 which represents
the multiplicative factor by which the ratio of the pre-
dicted odds of response for ETV and predicted odds for
LAM changes when the baseline log-PCR increases by
one unit. In other words, when the baseline log-PCR
increases by one unit from its mean value, the OR of
response for ETV compared to LAM decreases by 5.6%
(ie, (1–0.94)*100). The analysis at ≤300 copies/ml
found that the odds were similar, that is, 0.95. However,
it should be noted that the coefﬁcients are only margin-
ally signiﬁcant in both analyses (p=0.047 for ≤400
copies/ml and p=0.096 for ≤300 copies/ml). These
results show that there is evidence (albeit relatively
weak) to suggest that the treatment effect may be mod-
erated by the level of baseline log-PCR.
The interaction analysis of treatment and TIME in the
GEE model is also statistically signiﬁcant (p=0.00) for both
response deﬁnitions. This indicates that the treatment
effect is moderated by time-of-response measurement.
The positive coefﬁcient on the interaction variable sug-
gests that when time-of-response measurement increases
by 1 week, the OR of response for ETV compared to LAM
increases by 3.9%. This indicates that, while the odds of
achieving undetectable levels of HBV DNA increases with
time in both treatment groups, the rate of change in odds
is higher for ETV compared to LAM. We also evaluated
the interaction between HBeAg status and treatment
effect which was found to be statistically non-signiﬁcant in
both analyses. This result shows that there is no evidence
to suggest that the odds of response for ETV compared to
LAM is moderated by the HBeAg status.
CONCLUSION
This study evaluated the effect of interaction between
treatment received and the baseline characteristics and
Ali S, Mealing S, Hawkins N, et al. BMJ Open 2013;3:e001309. doi:10.1136/bmjopen-2012-001309 3
Impact of baseline characteristics on CHB response
group.bmj.com on December 12, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 1 Baseline HBV DNA levels by study
Baseline HBV DNA levels (log10 copies/ml)
Study Treatment HBeAg Positive HBeAg Negative
018 Study Group TBV 600 mg 9.57
ADV 10 mg 9.98
ADV 437 Study Group Placebo 8.12
ADV 10 mg 8.25
Study AI463-022 ETV 0.5 mg 9.62
LAM 100 mg 9.69
Cooksley 2003 IFNA 9.29
PegIFNA 9.25
Hou 2008 TBV 600 mg 9.3
LAM 100 mg 9.7
Lau 2005 PegIFNA 9.9
LMV 100 mg 10.1
Leung 2009 ETV 0.5 mg 10.3
ADV 10 mg 9.88
Marcellin 2008 TDF 300 mg 8.64
ADV 10 mg 8.88
Ren 2007 LAM 100 mg 8.49
ETV 0.5 mg 8.52
Shindo 2009 LAM 100 mg 7.94
ETV 0.5 mg 8.39
USLIG Placebo 5.7
LAM 100 mg 10.2
Placebo 8.6
AI463023 ETV 0.5 mg 8.8 7.7
LAM 100 mg 8.7 7.6
Globe study group LAM 100 mg 9.5 7.4
TBV 600 mg 9.5 7.7
Study AI463-027 ETV 0.5 mg 7.6
LAM 100 mg 7.6
Chan 2007 Placebo 5.6
LAM100 mg 5.7
Hou 2008 TBV 600 mg 7.8
LAM 100 mg 7.6
Marcellin 2004 PegIFNA 7.1
LAM 100 mg 7.2
Marcellin 2008 TDF 300 mg 6.9
ADV 10 mg 7.0
ADV, adefovir dipivoxil; ETV, entecavir; HBV, hepatitis B virus; LAM, lamivudine ; TBV, telbivudine; TDF, tenofovir disoproxil fumerate.
Table 2 Log-odds of response based on generalised estimating equation for treatment response at ≤400 copies/ml
Variables Log-odds SE z P>|z| (95% CI)
Constant 1.618 1.118 1.450 0.148 −0.573 to 3.809
Main effects
LPCR_0 (centred) −0.172 0.020 −8.490 0.000 −0.212 to −0.132
Treatment, ETV 1.563 0.224 6.990 0.000 1.124 to 2.001
HBeAg (positive) −1.277 0.567 −2.250 0.024 −2.387 to −0.166
Time (centred at 48 weeks) 0.022 0.005 4.480 0.000 0.012 to 0.031
Clinical study (ID=27)/ −0.306 0.558 −0.550 0.583 −1.399 to 0.787
Interaction terms
ETV * time (centred at 48 weeks) 0.039 0.008 5.040 0.000 0.024 to 0.054
ETV *PCR (centred at 48 weeks) −0.059 0.030 −1.980 0.047 −0.117 to −0.001
ETV * HBeAg (positive) 0.267 0.249 1.070 0.284 −0.221 to 0.754
ETV, entecavir.
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time-of-response measurement in predicting the odds of
treatment response (deﬁned as undetectable HBV DNA
levels at threshold values of 400 and 300 copies/ml).
The baseline variables included the log of baseline HBV
DNA level, the time-of-response measurement (in
weeks) and HBeAg status. While the qualitative relation-
ship between time, baseline viral load and response has
been documented in the literature,13 the key aim of the
analysis was to identify and quantify the interaction
effects that may act as treatment-effect modiﬁers which,
in turn, may be useful to adjust baseline differences in
future meta-analyses.
The analyses presented in this paper showed that
there is strong evidence to suggest that time-of-response
measurement may act as treatment-effect modiﬁer. This
suggests that time of measurement should be taken into
account during NMA, when clinical trials with different
periods of patient follow-up are included in the analysis.
Our analysis also found that there is weak evidence to
suggest that the baseline HBV DNA level may also inter-
act with treatment effect. This is potentially an import-
ant ﬁnding to suggest that future network meta-analyses
should evaluate the need to account for differences in
baseline disease activity in CHB patients. We also evalu-
ated the main (non-interactive) impact of baseline HBV
DNA level on odds of response in the models. The coef-
ﬁcient suggests that patients with more severe or
advanced levels of disease activity before treatment initi-
ation (as measured by baseline viral load) are less likely
to achieve response (as measured by response viral load)
at any given time point, that is, higher baseline disease
activity predicts worse response. This is in line with
earlier ﬁndings.
We did not ﬁnd any signiﬁcant interaction between
treatment-effect and HBeAg status. However, HBeAg
status was found to be a signiﬁcant predictor as a main
effect suggesting that patients with positive HBeAg status
are less likely to achieve response after controlling for
baseline HBV DNA and time-of-response measurement.
Reimbursement agencies, such as NICE, typically
make decisions based on evidence regarding relative
treatment effects based on clinical efﬁcacy data on end-
points, such as the level of response achieved after treat-
ment for a certain period of time, as a surrogate for
clinical efﬁcacy.14 From the perspective of a reimburse-
ment agency, the key ﬁnding of this analysis is that the
time-of-response measurement and baseline disease
activity may act as treatment-effect modiﬁers, suggesting
that when these variables are not distributed in a
balanced way across trials, there is potential for
Table 3 Log-odds of response based on generalised estimating equation for treatment response at ≤300 copies/ml
Variables Log-odds SE z P>|z| (95% CI)
Constant 1.817 1.128 1.610 0.107 −0.394 to 4.027
Main effects
LPCR_0 (centred) −0.166 0.020 −8.160 0.000 −0.205 to −0.126
Treatment, ETV 1.429 0.214 6.680 0.000 1.010 to 1.848
HBeAg (positive) −1.414 0.572 −2.470 0.013 −2.536 to −0.293
Time (centred at 48 weeks) 0.025 0.005 5.290 0.000 0.016 to 0.035
Clinical study (ID=27) −0.450 0.563 −0.800 0.424 −1.553 to 0.653
Interaction terms
ETV * Time (centered at 48 weeks) 0.035 0.007 4.710 0.000 0.020 to 0.049
ETV *PCR (centered at 48 weeks) −0.049 0.029 −1.660 0.096 −0.106 to 0.009
ETV * HBeAg (positive) 0.264 0.244 1.080 0.278 −0.213 to 0.742
ETV, entecavir; LPCR_0, natural log of baseline HBV DNA measured by PCR assay.
Table 4 Odds of response based on generalised estimating equation for treatment response at ≤400 copies/ml
Variables Odds SE z P>|z| (95% CI)
Main effects
LPCR_0 (centred) 0.842 0.017 −8.490 0.000 0.809 to 0.876
Treatment, ETV 4.773 1.068 6.990 0.000 3.079 to 7.400
HBeAg (positive) 0.279 0.158 −2.250 0.024 0.092 to 0.847
Time (centred at 48 weeks) 1.022 0.005 4.480 0.000 1.012 to 1.032
Clinical study (ID=27) 0.736 0.411 −0.550 0.583 0.247 to 2.196
Interaction terms
ETV * time (centred at 48 weeks) 1.039 0.008 5.040 0.000 1.024 to 1.055
ETV *PCR (centred at 48 weeks) 0.943 0.028 −1.980 0.047 0.889 to 0.999
ETV * HBeAg (positive) 1.305 0.325 1.070 0.284 0.801 to 2.126
ETV, entecavir; LPCR_0, natural log of baseline HBV DNA measured by PCR assay.
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confounding bias in the resulting meta-analysis estimates.
Hence, analysts should evaluate differences in patient-level
and study-level characteristics that may act as
treatment-effect modiﬁers while undertaking using direct,
indirect and mixed treatment comparisons to allow fair
‘like-for-like’ comparisons to be made. However, it should
be noted that the within-trial interaction analysis provides
an estimate of the magnitude of potential treatment-effect
modiﬁer rather than proving beyond doubt that these
interactions exist at the study level.
All mixed treatment comparisons of CHB treatments
published to date did not adjust for patient baseline
characteristics. Therefore, if heterogeneity or treatment
modiﬁers across clinical trials are not accounted for,
then meta-analysis may produce biased estimates in
favour of treatment(s) that had patients with relatively
longer time-of-response measurement and less severe
disease activity in the trials (ie, lower baseline risk).
Furthermore, when such evidence is incorporated in an
economic model, such as those developed by Dakin
et al15 or Veenstra et al,16 17 the cost-effectiveness esti-
mates may be biased against interventions that was
studied in patients with more severely disease activity.
Strengths and weaknesses of the analyses
The study used individual patient level data from two lon-
gitudinal randomised trials over a period of 48 weeks. The
statistical models took account of the longitudinal nature
of the data and the correlation between repeated mea-
sures. Interaction effects that may act as treatment-effect
modiﬁers were evaluated and quantiﬁed in this study.
One potential limitation of the study is that response
HBV DNA levels were observed at relatively small number
of discrete time points, that is, 24, 36 and 48 weeks. This
may have an implication on the statistical power of the
study to detect signiﬁcant effects. Another limitation is
that the relationship between treatment effect and
patient-level baseline characteristics was explored only in
the trials of ETV versus LAM in this study, and as such, we
were not able to explore treatment-effect modiﬁers in
other interventions such as adefovir and tenofovir. It is
difﬁcult to anticipate whether or not such interaction
effects will be observed in other CHB studies. However,
we do not know of any reasons why the observed relation-
ship may not hold for CHB patients receiving other treat-
ments. However, we would recommend that such analyses
are repeated in other randomised trials to ascertain the
validity of these ﬁndings. Finally, the analysis assumed
that the unobserved patient characteristics in this study
did not directly inﬂuence the observed relationship
between treatment-effect and baseline characteristics.
Implications for evidence synthesis
This study found that the time-of-response measurement
and the level of baseline disease activity may act as
treatment-effect modiﬁers in CHB patients. From the
perspective of evidence synthesis, this study identiﬁes an
important issue, that is, treatment-effect modiﬁers may
impact on the comparisons made across several studies
in meta-analyses. It highlights the need to explore the
impact of baseline characteristics and time-period imbal-
ances between studies included in meta-analyses. When
effect-modiﬁer relationships are signiﬁcant, comparisons
across treatments may not be fair and could potentially
bias the comparative treatment-effect estimates.
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